NASDAQ
3.07USD
-0.08 (-2.54%)
We have scored 3 news catalysts on Nephros, Inc. (NEPH) over the past 12 months. The biggest single-day move next to one of them came Feb 13, 2026, when NEPH closed +9.0%: “Nephros Expands into Puerto Rico to Deliver Differentiated Water Filtration Solutions Across Medical and Commercial Sectors”. Coverage across the window leans positive (average ticker sentiment +0.80). Most of the impact sits in pricing power structural and forward growth expectations.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
33.4M
P/E
—
EPS
—
Beta
1.75
52W range
2.66-6.42
Day range
3.03–3.18
Open
3.17
Prev close
3.15
Volume
32.7K
Avg volume
35.1K
Dividend
0.00
IPO
2004-09-21
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Nephros, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for NEPH: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Nephros, Inc. is a company that specializes in developing and marketing sophisticated water purification solutions across the United States, catering to both the medical and commercial sectors. Its operations are structured into three primary segments: Water Filtration, Pathogen Detection, and Renal Products. Within its Water Filtration division, Nephros offers advanced ultrafiltration products. These are vital in dialysis centers for eradicating biological contaminants from water and bicarbonate concentrate, and are also deployed in hospitals to prevent infections from waterborne pathogens such as Legionella and Pseudomonas. Their utility extends to military installations, outdoor recreation, commercial establishments, and various other healthcare facilities. The Pathogen Detection segment focuses on developing and distributing real-time water testing systems, which deliver critical, actionable data regarding waterborne pathogens. Furthermore, under its Renal Products segment, the company provides medical devices designed for individuals suffering from renal disease, notably including a second-generation hemodiafiltration system tailored for patients with end-stage renal disease. Additionally, Nephros markets a range of water filters under the Nephros and AETHER brands. These filters are engineered not only to enhance water taste and eliminate odors but also to significantly reduce biofilm, bacteria, and scale accumulation in downstream equipment, serving the food service, hospitality, convenience store, and healthcare industries. Established in 1997, Nephros, Inc. maintains its corporate headquarters in South Orange, New Jersey.
